Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
Jean‐Luc Raoul, Jean‐Sébastien Frenel, Judith Raimbourg et al. · Hepatic Oncology · 2019
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosine kinase inhibitor available in first line, lenvatinib, three other targeted therapies in second line post-sorafenib (regorafenib, cabozantinib and ramucirumab) and promising data from two immunotherapies (nivolumab and pembrolizumab). Unfortunately, no biomarkers have been identified to help guide our choice. In this short review we summarize the results of these different therapies and propose a therapeutic algorithm based on subgroup analysis. It is most likely that we will not have head-to-head comparisons in second line trials.
Cited by 35 works. doi:10.2217/hep-2019-0001 Open-access PDF
Authors
References
- Sorafenib in Advanced Hepatocellular Carcinoma
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- Hepatocellular carcinoma
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma